Edition:
United Kingdom

Cigna Corp (CI.N)

CI.N on New York Stock Exchange

197.87USD
15 Feb 2019
Change (% chg)

$5.65 (+2.94%)
Prev Close
$192.22
Open
$193.85
Day's High
$198.13
Day's Low
$193.10
Volume
642,136
Avg. Vol
643,577
52-wk High
$226.58
52-wk Low
$163.02

Latest Key Developments (Source: Significant Developments)

IBM Says Cigna And Sentara Healthcare Join New Health Utility Network Using Blockchain
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - International Business Machines Corp ::CIGNA AND SENTARA HEALTHCARE EXPAND BLOCKCHAIN-BASED ECOSYSTEM FOR HEALTHCARE INDUSTRY - ALONG WITH AETNA, ANTHEM, HEALTH CARE SERVICE CORPORATION, PNC BANK AND IBM.IBM - CIGNA AND SENTARA HEALTHCARE HAVE JOINED A NEW HEALTH UTILITY NETWORK USING BLOCKCHAIN.  Full Article

Cigna Corp Qtrly Total Revenue $14,300 Mln Vs $10,632 Mln
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Cigna Corp ::CIGNA DELIVERS STRONG 2018 RESULTS AS IT COMPLETES EXPRESS SCRIPTS TRANSACTION; COMPANY POSITIONED FOR SIGNIFICANT GROWTH.QTRLY TOTAL REVENUE $14,300 MILLION VERSUS $10,632 MILLION.CIGNA - ADJUSTED REVENUES ARE EXPECTED TO GROW TO A RANGE OF $131.5 BILLION TO $133.5 BILLION IN 2019.QTRLY EARNINGS PER SHARE $0.55.QTRLY ADJUSTED. EARNINGS PER SHARE $2.46.Q4 EARNINGS PER SHARE VIEW $2.42, REVENUE VIEW $11.59 BILLION -- REFINITIV IBES DATA.ADJUSTED INCOME FROM OPERATIONS IS PROJECTED TO BE IN RANGE OF $6.2 BILLION TO $6.4 BILLION IN 2019.2019 ADJUSTED INCOME FROM OPERATIONS IS PROJECTED TO BE IN RANGE OF $16.00 TO $16.50 PER SHARE.FY2019 EARNINGS PER SHARE VIEW $16.74, REVENUE VIEW $133.60 BILLION -- REFINITIV IBES DATA.SEES 2019 MEDICAL CARE RATIO OF 80.5% TO 81.5%.SEES 2019 MEDICAL CUSTOMER GROWTH OF 300,000 TO 400,000 CUSTOMERS.RECORDED TRANSACTION-RELATED COSTS $402 MILLION IN QUARTER.  Full Article

Anthem Reports Q4 Adjusted Earnings Per Share $2.44
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - Anthem Inc ::ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS REFLECTING STRONG CORE PERFORMANCE.Q4 ADJUSTED EARNINGS PER SHARE $2.44.Q4 EARNINGS PER SHARE $1.61.Q4 EARNINGS PER SHARE ESTIMATE $2.20 -- REFINITIV IBES DATA.Q4 REVENUE $23.3 BILLION VERSUS REFINITIV IBES ESTIMATE OF $23.35 BILLION.FULL YEAR 2019 NET INCOME IS EXPECTED TO BE GREATER THAN $18.00 PER SHARE.FULL YEAR 2019 ADJUSTED NET INCOME IS EXPECTED TO BE GREATER THAN $19.00 PER SHARE.FULL YEAR 2019 MEDICAL MEMBERSHIP IS EXPECTED TO BE IN RANGE OF 40,900,000 - 41,300,000.QUARTERLY DIVIDEND INCREASED BY 6.7% TO $0.80 PER SHARE.QTRLY MEDICAL ENROLLMENT DECLINED BY 361 THOUSAND MEMBERS FROM 40.3 MILLION MEMBERS AT DECEMBER 31, 2017.FULL YEAR 2019 OPERATING REVENUE IS EXPECTED TO BE APPROXIMATELY $100.0 BILLION, INCLUDING PREMIUM REVENUE OF $90.5 BILLION - $92.5 BILLION.FULL YEAR 2019 BENEFIT EXPENSE RATIO IS EXPECTED TO BE IN RANGE OF 86.2% PLUS OR MINUS 30 BASIS POINTS.FULL YEAR 2019 FULLY-INSURED MEMBERSHIP IS EXPECTED TO BE IN RANGE OF 15,500,000 - 15,700,000.FY2019 EARNINGS PER SHARE VIEW $17.61, REVENUE VIEW $97.65 BILLION -- REFINITIV IBES DATA.BENEFIT EXPENSE RATIO WAS 86.8 PERCENT IN Q4, DOWN 180 BASIS POINTS FROM 88.6 PERCENT IN PRIOR YEAR QUARTER.FULL YEAR 2019 SELF-FUNDED MEMBERSHIP IS EXPECTED TO BE IN RANGE OF 25,400,000 - 25,600,000.ANTICIPATES LOCAL GROUP MEDICAL COST TREND WILL BE IN RANGE OF 6.0% +/- 50 BPS IN 2019.INGENIORX NOW SCHEDULED TO LAUNCH IN 2Q 2019.  Full Article

Cigna Corp Intends To Affirm Express Scripts Holding's Expectation For Growth In Core Business Adjusted Claims In 2019
Monday, 7 Jan 2019 

Jan 7 (Reuters) - :CIGNA CORP - INTENDS TO AFFIRM EXPRESS SCRIPTS HOLDING CO'S EXPECTATION FOR GROWTH OF 2% TO 3% IN CORE BUSINESS ADJUSTED CLAIMS IN 2019.CIGNA CORP - CO AND OPTUMRX HAVE ENTERED INTO MUTUAL AGREEMENT FOR TRANSITION OF PHARMACY BENEFIT MANAGEMENT SERVICES CURRENTLY PROVIDED BY OPTUMRX.CIGNA - EXPECT TO DISCLOSE EXPECTATIONS FOR 2019 GROWTH , WITH GLOBAL MEDICAL CUSTOMER GROWTH OF 300,000 TO 400,000 CUSTOMERS OVER 2018 - SEC FILING.CIGNA CORP - ALL SERVICES EXPECTED TO BE TRANSITIONED AND COMPLETED BY DECEMBER 31, 2020.CIGNA CORP - GROWTH IN 2019 EXPECTATIONS INCLUDE MID-SINGLE DIGIT PERCENT GROWTH IN INDIVIDUAL MEDICARE ADVANTAGE CUSTOMERS OVER YEAR-END 2018.  Full Article

Cigna Says Receives All Required Regulatory Approvals For Express Scripts Deal
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Cigna Corp ::CIGNA CORP - CO, EXPRESS SCRIPTS RECEIVED REGULATORY APPROVAL FROM STATE OF NEW JERSEY FOR MERGER.CIGNA CORP - ALL REQUIRED REGULATORY APPROVALS FOR THE DEAL NOW HAVE BEEN RECEIVED AND PARTIES EXPECT TO CLOSE TRANSACTION ON DECEMBER 20, 2018.  Full Article

Australia And New Zealand Banking Group Says ANZ NZ Completes Sale Of Onepath Life (NZ) Ltd
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Australia And New Zealand Banking Group Ltd ::ANZ NZ COMPLETES SALE OF ONEPATH LIFE (NZ) TO CIGNA-ANZ.AX.COMPLETED SALE OF ONEPATH LIFE (NZ) LIMITED TO CIGNA CORPORATION.  Full Article

Management Solutions to set up JV in Shanghai
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Management Solutions Co Ltd <7033.T>:Says it will set up a Shanghai-based management consultation JV in December .Says the JV will be capitalized at 50 million yen .Says it will hold 80 percent stake in the JV .  Full Article

Cigna CEO Says Continues To Expect To Close Express Scripts Deal By End Of The Year
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Cigna Corp ::CEO SAYS EXPRESS SCRIPTS <<>> DEAL HAS GAINED REGULATORY APPROVAL ACROSS 23 STATES, WITH 6 APPROVALS REMAINING - CONF CALL.CEO SAYS CO CONTINUES TO EXPECT TO CLOSE EXPRESS SCRIPTS DEAL BY THE END OF THE YEAR - CONF CALL.CIGNA CEO SAYS MARGINS IN U.S. INDIVIDUAL BUSINESS WERE HIGHER THAN ANTICIPATED THIS YEAR BUT LIKELY TO BE "MORE IN LINE" WITH EXPECTATIONS IN 2019.CIGNA SAYS FOR NOW 2021 ADJUSTED. EPS TARGET REMAINS IN THE RANGE OF $20-$21.  Full Article

Express Scripts Q3 Adjusted Earnings Per Share $2.43
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Express Scripts Holding Co ::EXPRESS SCRIPTS ANNOUNCES 2018 THIRD QUARTER RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $2.43.Q3 GAAP EARNINGS PER SHARE $1.89.Q3 EARNINGS PER SHARE VIEW $2.43 -- THOMSON REUTERS I/B/E/S.QTRLY REVENUE $25,563.2 MILLION VERSUS $24,683.4 MILLION REPORTED LAST YEAR.QTRLY ADJUSTED CLAIMS OF 334.6 MILLION, DOWN 2.6%.EXPECTS 2019 RETENTION RATE FOR 2018 SELLING SEASON TO EXCEED 98%.EXPECT TO GROW CORE BUSINESS ADJUSTED CLAIMS BY 2% TO 3% IN 2019.Q3 REVENUE VIEW $25.04 BILLION -- THOMSON REUTERS I/B/E/S.CIGNA MERGER IS EXPECTED TO BE COMPLETED BY DECEMBER 31, 2018.EXPRESS SCRIPTS - DUE TO PENDING ACQUISITION BY CIGNA, WILL NOT BE HOLDING A Q3 CONFERENCE, WILL NO LONGER PROVIDE FINANCIAL GUIDANCE.  Full Article

Cigna Announces Enterprise Leadership Team For Combined Company
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Cigna Corp ::CIGNA ANNOUNCES ENTERPRISE LEADERSHIP TEAM FOR COMBINED COMPANY.EXPRESS SCRIPTS PRESIDENT AND CEO TIM WENTWORTH WILL HEAD HEALTH SERVICES BUSINESS AS PRESIDENT, EXPRESS SCRIPTS AND CIGNA SERVICES.ERIC PALMER WILL BE THE CHIEF FINANCIAL OFFICER OF THE COMBINED CO AFTER EXPRESS SCRIPTS MERGER.CHANGES EFFECTIVE UPON COMPLETION OF EXPRESS SCRIPTS MERGER, EXPECTED BY YEAR-END 2018.COMBINED CO WILL OFFER PLATFORMS SUCH AS A COMMERCIAL BUSINESS, A GOVERNMENT. BUSINESS, INTERNATIONAL BUSINESS & A HEALTH SERVICES BUSINESS.COMBINED CO'S HEALTH SERVICES BUSINESS WILL INCLUDE EXPRESS SCRIPTS.  Full Article

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.